Overview |
bsm-41203M-APC |
phospho-Alpha synuclein(Ser129) Monoclonal Antibody, APC Conjugated |
WB, FCM, IF(ICC) |
Human, Mouse, Rat |
Specifications |
APC |
Mouse |
KLH conjugated Synthesised phosphopeptide derived from human alpha-synuclein around the phosphorylation site of Ser129 |
Monoclonal |
6B7 |
IgG |
1ug/ul |
Purified by Protein A. |
Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
Target |
6622 |
P37840 |
Cytoplasm, Nucleus, Cytomembrane |
Alpha-synuclein (phospho S129); Alpha-synuclein (p-S129); Alpha synuclein; Alpha-Synuclein; Alpha-synuclein, isoform NACP140; alpha SYN; MGC105443; MGC110988; MGC127560; MGC64356; NACP; Non A beta component of AD amyloid; Non A4 component of amyloid precursor; Non-A-beta component of alzheimers disease amyloid , precursor of; Non-A beta component of AD amyloid; Non-A4 component of amyloid precursor; PARK 1; PARK 4; PARK1; PARK4; Parkinson disease (autosomal dominant, Lewy body) 4; Parkinson disease familial 1; PD 1; PD1; Syn; SNCA; Snca synuclein, alpha (non A4 component of amyloid precursor); SYUA_HUMAN; Synuclein alpha; Synuclein, alpha (non A4 component of amyloid precursor); |
May be involved in the regulation of dopamine release and transport. Induces fibrillization of microtubule-associated protein tau. Reduces neuronal responsiveness to various apoptotic stimuli, leading to a decreased caspase-3 activation. |
Application Dilution |
WB |
1:300-5000 |
FCM |
1:20-100 |
IF(ICC) |
1:50-200 |